In the study “Pembrolizumab-associated sarcoidosis,” researchers described the first case of sarcoidosis after a patient was treated with after Keytruda (pembrolizumab) to inhibit the programmed cell death-1 (PD-1) receptor. The study was published in the JAAD Case Reports journal. Keytruda is a humanized antibody that targets the PD-1…
News
When skin sarcoidosis is associated with pre-existing scars, it is called scar sarcoidosis. In a recent study, researchers at the Chungnam National University School of Medicine in Korea reported the case of a patient who developed scar sarcoidosis following pulsed dye laser treatment for a pre-existing scar. The study, “…
Sarcoidosis patients appear to have unusual energy production and transmethylation of proteins, as well as an abnormal gut microbiota, according to researchers at Wayne State University School of Medicine and colleagues, who compared the metabolites found in sarcoidosis patients with those of healthy people. The study, “Metabolomics connects aberrant bioenergetic, transmethylation,…
Cancer immunotherapy with Opdivo (nivolumab) and Yervoy (ipilimumab) may or may not trigger sarcoidosis in rare cases, a report from Yale University School of Medicine shows. The study, “Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy,” published in the Journal of the American Academy of…
The study “Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis,” published recently in PLOS One, links some patients with sarcoidosis to the development of the disease and the presence of mycobacterium tuberculosis, which causes tuberculosis. Mycobacterium tuberculosis is the second leading cause of death by infectious disease, preceded only…
Psoriasiform lesions are a rare but established manifestation of sarcoidosis, in which psoriasis plaques are formed within sarcoidosis skin lesions. In a recent study, researchers at Thomas Jefferson University in Philadelphia and the University of Miami in Florida presented a case report of a patient with psoriasiform sarcoidosis, and discussed the…
Researchers at the University of Washington in Seattle identified numerous gene pathways that are altered in sarcoidosis, not only confirming the involvement of the innate immune system, but also demonstrating that systems for protein breakdown are activated in the disease. The study, “Sarcoidosis activates diverse transcriptional…
Relief Therapeutics, readying for a pivotal clinical trial of a sarcoidosis treatment, announced that it is acquiring FirstString Research in an all-stock transaction that will add an advanced clinical stage product, Granexin, a potential treatment for diabetic foot ulcers and venous leg ulcers, to its drug portfolio. Relief will also acquire FirstString’s pipeline…
Researchers at Jichi Medical University in Japan reported a case of sarcoidosis relapse in a woman who developed renal dysfunction, high calcium levels, as well as kidney and urethral stones. The report, “Renal Failure Found during the Follow-up of Sarcoidosis: The Relevance of a Delay in…
Analyzing the bronchoalveolar lavage fluid (called BALF, it is a small sample of the fluid present in the lungs) for the ratio of immune CD4 and CD8 cells may improve the diagnosis of sarcoidosis, according to the results of a recent study. BALF is collected through a medical procedure using a bronchoscope that is…
Recent Posts
- New AI model predicts sudden cardiac death risk better in cardiac sarcoidosis
- FSR invests $400K in 4 early-stage sarcoidosis research projects
- The questions of menopause mirror the uncertainty of sarcoidosis
- 7 new institutions join FSR alliance to improve treatment of sarcoidosis
- Simple blood test may predict cardiac sarcoidosis outcomes
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF